Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to fulfilling the promise of precision medicines for the treatment of cancer. The company's pipeline consists of two wholly-owned small molecule drug candidates targeting cancer signaling pathways, with strong scientific and clinical rationale to improve outcomes by identifying patients most likely to benefit from the treatment. Kura’s most advanced candidate is tipifarnib, a potent, selective, orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) for patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma.